(Q44306236)

1 December 2017

title

Non-adrenergic exploratory behavior induced by moxonidine at mildly hypotensive doses (English)

1 reference

1 December 2017

He Zhu

1

1 reference

1 December 2017

Ian A Paul

2

1 reference

1 December 2017

David E Stec

3

1 reference

1 December 2017

Dudley F Peeler

4

1 reference

1 December 2017

John E Piletz

5

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

1 December 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

Brain Research

1 reference

1 December 2017

volume

964

1 reference

1 December 2017

issue

1

1 reference

1 December 2017

page(s)

9-20

1 reference

Alpha2C-adrenoceptor-overexpressing mice are impaired in executing nonspatial and spatial escape strategies.

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

The noradrenergic alpha2 agonist clonidine modulates behavioural and neuroanatomical correlates of human attentional orienting and alerting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

'Seeing through a glass darkly': casting light on imidazoline 'I' sites.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Behavioral effects of neurotensin in the open field: structure-activity studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Moxonidine, a selective imidazoline/alpha(2) adrenergic receptor agonist, synergizes with morphine and deltorphin II to inhibit substance P-induced behavior in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Effects of the selective I1 imidazoline receptor agonist, moxonidine, on gastric secretion and gastric mucosal injury in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of ?fear?-motivated behaviour

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

I1-imidazoline receptors and cholinergic outflow to the airways.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Central imidazoline- and alpha 2-receptors involved in the cardiovascular actions of centrally acting antihypertensive agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Mediation of the hypotensive action of systemic clonidine in the rat by alpha 2-adrenoceptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Reduced sympathetic nervous system responsivity associated with the relaxation response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Coupling of human alpha 2-adrenoceptor subtypes to regulation of cAMP production in transfected S115 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Binding of [3H]p-aminoclonidine to two sites, alpha 2-adrenoceptors and imidazoline binding sites: distribution of imidazoline binding sites in rat brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

The use of a plus-maze to measure anxiety in the mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Circulatory effects at rest and exercise of clonidine, an imidazoline derivative with hypotensive properties.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Imidazoline receptor antisera-selected (IRAS) cDNA: cloning and characterization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Autoradiographic comparison of [3H]-clonidine binding to non-adrenergic sites and alpha(2)-adrenergic receptors in human brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Relationship between imidazoline/guanidinium receptive sites and monoamine oxidase A and B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Pharmacologic and therapeutic applications of alpha 2-adrenoceptor subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Excess catecholamines and the metabolic syndrome: Should central imidazoline receptors be a therapeutic target?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Genetic alteration of the alpha2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Genetic alteration of alpha 2C-adrenoceptor expression in mice: influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtype-nonselective alpha 2-adrenoceptor agonist.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Safety and tolerability of moxonidine in the treatment of hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Evaluation of the alpha2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Activation of phosphatidylcholine-selective phospholipase C by I1-imidazoline receptors in PC12 cells and rostral ventrolateral medulla.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Guanabenz effects on blood pressure and noninvasive parameters of cardiac performance in patients with hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Efficient liver-specific deletion of a floxed human angiotensinogen transgene by adenoviral delivery of Cre recombinase in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

D3 dopamine receptor-deficient mouse: evidence for reduced anxiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Heterozygous alpha 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

alpha(2)-adrenergic receptors are not required for central anti-hypertensive action of moxonidine in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Thigmotaxis as a test for anxiolytic activity in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Central imidazoline (I1) receptors as targets of centrally acting antihypertensives: moxonidine and rilmenidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Moxonidine, a selective imidazoline-1 receptor agonist, suppresses the effects of ethanol withdrawal on the acoustic startle response in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Interactions between clonidine and antidepressant drugs: a method for identifying antidepressant-like agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Moxonidine and cognitive function: interactions with moclobemide and lorazepam.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2802%2903754-X

10.1016/S0006-8993(02)03754-X

7 January 2021

Identifiers

DOI

1 reference

1 December 2017

1 reference